Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life

Europace

Volumn 12, Issue 5, 2010, Pages 634-642

  Guédon Moreau, Laurence ^a   Capucci, Alessandro ^b   Denjoy, Isabelle ^c   Morgan, Caroline Claire ^d   Périer, Antoine ^d   Leplége, Alain ^e   Kacet, Salem ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c HÔPITAL LARIBOISIÈRE   (France)

^d Cardinal Systems   (France)

^e BICÊTRE HOSPITAL   (France)

Author keywords

Antiarrhythmic drug; Paroxysmal atrial fibrillation; Quality of life; Reference population

Indexed keywords

FLECAINIDE ACETATE; ANTIARRHYTHMIC AGENT; FLECAINIDE;

ADULT; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; AGED; ATRIAL FIBRILLATION; CLINICAL TRIAL; COMPARATIVE STUDY; COST OF ILLNESS; HEALTH SURVEY; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; PSYCHOLOGY; SELF DISCLOSURE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COST OF ILLNESS; FEMALE; FLECAINIDE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; QUALITY OF LIFE; SELF DISCLOSURE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77951955865     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euq007     Document Type: Article

References (30)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 2006;114: e257-e354.
2. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. Rate control versus electrical cardioversion for persistent atrial fibrillation study group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
3. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al., Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
4. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003;41:1690-6.
5. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000;36:1303-9.
6. Reynolds MR, Ellis E, Zimetbaum P. Quality of life in atrial fibrillation: Measurement tools and impact of interventions. J Cardiovasc Electrophysiol 2008;19:762-8.
7. Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchett EL. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol 1994;74:826-9.
8. Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 1996;94:1585-91.
9. Wade JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Med Care 1992;30:473-83.
10. Maglio C, Sra J, Paquette M, Dorian P, Bygrave AJ, Wood K et al. Measuring quality of life and symptom severity in patients with atrial fibrillation. Pacing Clin Electrophysiol 1998;21:839.
11. Thrall G, Lane D, Carrol D, Lip GYH. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448. E1-19.
12. Dorian P, Paquette M, Newman D, Green M, Connolly SJ, Talajic M et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 2002;143:984-90.
13. Lonnerholm S, Blomstrom P, Nilsson L, Oxelbark S, Jideus L, Blomstrom-Lundqvist C. Effects of the maze operation on health-related quality of life in patients with atrial fibrillation. Circulation 2000;101:2607-11.
14. Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled non randomized long-term study. J Am Coll Cardiol 2003;42:185-97.
15. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL et al., Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72.
16. Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J 2006;152:1097-103.
17. Hohnloser SH, Zabel M. Short-and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol 1992;70:3-9A; discussion 9-10A.
18. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989;80:1557-70.
19. Anderson JL, Jolivette DM, Fredell PA. Summary of efficacy and safety of flecainide for supraventricular arrhythmias. Am J Cardiol 1988;62:62-6D.
20. Pritchett EL, DaTorre SD, Platt ML, McCarville SE, Hougham AJ. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. J Am Coll Cardiol 1991;17:297-303.
21. Henthorn RW, Waldo AL, Anderson JL, Gilbert EM, Alpert BL, Bhandari AK et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation 1991;83:119-25.
22. Anderson JL. Long-term safety and efficacy of flecainidein the treatmentofsupraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators. Am J Cardiol 1992;70:11-7A; discussion 17-8A.
23. Benditt DG, Dunnigan A, Buetikofer J, Milstein S. Flecainide acetate for long-term prevention of paroxysmal supraventricular tachyarrhythmias. Circulation 1991;83:345-9.
24. Chouty F, Coumel P. Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. Am J Cardiol 1988;62:35-7D.
25. Wheeling M. Metaanalysis of flecainide safety in patients with supra-ventricular arrhythmias. Arnzneim Forsch Drug Res 2002;52:507-14.
26. Tenneze L, Tarral E, Ducloux N, Funck-Brentano C. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. Clin Pharmacol Ther 2002;72:112-22.
27. Paquette M, Roy D, Talajic M, Newman D, Couturier A, Yang C et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol 2000;86:764-8.
28. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988. p25.
29. Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG et al., RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004;43:241-7. (Pubitemid 38201151)
30. Dorian P, Mangat I. Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation. Card Electrophysiol Rev 2003;7:276-9.